Announcements Trials
Browse Landscape

Status

Completed 22Terminated 8Unknown 7Recruiting 4Active not recruiting 4Withdrawn 2Not yet recruiting 2No longer available 1

Sponsor Class

INDUSTRY 1

Study Type

Expanded_access 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Multiple Myeloma 15Melanoma 14Carcinoma, Non-Small-Cell Lung 13Recurrence 12Neoplasms 12Leukemia, Myeloid, Acute 9Glioblastoma 8Prostatic Neoplasms 6Lung Neoplasms 6Breast Neoplasms 6Lymphoma 5Glioma 5Carcinoma, Renal Cell 5Sarcoma 4Pancreatic Neoplasms 4Lymphoma, Non-Hodgkin 4Gastrointestinal Stromal Tumors 4Colorectal Neoplasms 4Triple Negative Breast Neoplasms 3Precursor Cell Lymphoblastic Leukemia-Lymphoma 3Leukemia, Myelogenous, Chronic, BCR-ABL Positive 3Carcinoma 3Solid Tumors 2Small Cell Lung Carcinoma 2Ovarian Neoplasms 2Neoplasms by Site 2Lymphoma, T-Cell, Cutaneous 2Lymphoma, Large-Cell, Anaplastic 2Liver Neoplasms 2Leukemia 2

Interventions

derazantinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
No longer available × INDUSTRY × Bile Duct Neoplasms × Clear all
NCT04087876 2025-04-06

Expanded Access Use of Derazantinib for Advanced Intrahepatic Cholangiocarcinoma (iCCA) With FGFR Genomic Alterations

Basilea Pharmaceutica

No longer available
Gastrointestinal

Bile Duct Neoplasms, Biliary Tract Neoplasms, Liver Neoplasms, Cholangiocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡